Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy

December 2018 Vol 11, No 9 - Conference Correspondent
Download PDF

The randomized, controlled Omadacycline in Acute Skin Structure Infections Study (OASIS)-2 study comparing omadacycline and linezolid for the treatment of adults with an acute bacterial skin and skin structure infection (ABSSSI) that is known or suspected to result from a gram-positive pathogen enrolled 735 patients, with 368 and 367 patients in each group, respectively.1 Patients completed the 36-Item Short Form Health Survey, version 2 (SF-36v2), a validated questionnaire on physical and mental health.

The results of the SF-36v2 were based on the standards for the intention-to-treat population.2 Patients who received omadacycline had a 3.25-point mean improvement in overall physical health (P <.001 vs baseline) and reported significant improvements across all but 1 parameter of overall health, including physical functioning, bodily pain, role physical, vitality, role emotional, mental health, and social functioning. In contrast, although the overall physical health improved with linezolid, the improvement in vitality, role emotional, mental health, and general health was not significant. Patients who received omadacycline achieved a greater improvement from baseline than the linezolid group across all quality-of-life (QOL) domains; the difference was not statistically significant.

Omadacycline significantly improves the physical component of QOL over baseline for adults with ABSSSI resulting from a gram-positive pathogen, and demonstrates a numerically greater improvement in QOL than linezolid.

1. Tzanis E, Chitra S, Curran M, et al. Improvement in quality of life for adults with acute bacterial skin and skin structure infections following treatment with omadacycline or linezolid. Presented at IDWeek 2018; San Francisco, CA; October 3-7, 2018.
2. Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:3130-3139. Erratum in: Spine (Phila Pa 1976). 2001;26:2062.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: January 2, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME